为肝细胞癌武装 GPC3 CAR-T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:FYN/LCK kinase balance as a metabolic switch orchestrates progenitor-exhausted T-cell differentiation in hepatocellular carcinoma.
FYN/LCK kinase balance as a metabolic switch orchestrates progenitor-exhausted T-cell differentiation in hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究确立了 FYN/LCK 平衡是通过代谢重编程调控 Tpex 细胞终末耗竭的关键调节因子。这些发现表明,调节 FYN/LCK 激酶平衡是克服 HCC 免疫治疗耐药的一种有前景的策略。
免疫检查点阻断(ICB)在肝细胞癌(HCC)中显示出治疗前景,但在患者中与次优反应相关。祖细胞耗竭T(Tpex)细胞是ICB的关键反应细胞,但调控HCC中Tpex维持的机制仍不清楚。方法与结果:通过对HCC单细胞RNA测序数据集的整合分析,我们构建了耗竭CD8+ T细胞图谱,并鉴定出激酶FYN作为ICB反应者中Tpex细胞的标志物。CD8+ T细胞中FYN缺陷诱导LCK过度活化,在高亲和力抗原刺激下驱动终末耗竭。机制上,LCK过度活化通过触发过度糖酵解和损害Tpex细胞线粒体功能,破坏代谢稳态。相反,LCK抑制提高了代偿性FYN活性,恢复了线粒体适应性,并保留了Tpex细胞干性。在临床前HCC模型中,T细胞扩增期间短暂LCK抑制通过增加Tpex细胞持久性和干性,增强了过继细胞治疗疗效。此外,在抗PD-1治疗前预防性低剂量LCK抑制扩大了Tpex细胞池,减少了终末耗竭,并改善了治疗结果。
BACKGROUND AND AIMS: Immune checkpoint blockade (ICB) shows therapeutic promise in hepatocellular carcinoma (HCC) but is associated with suboptimal responses in patients. Progenitor-exhausted T (Tpex) cells are key responders to ICB, but the regulatory mechanisms governing Tpex maintenance in HCC remain elusive. APPROACH AND RESULTS: Through an integrated analysis of HCC single-cell RNA-sequencing datasets, we constructed an exhausted CD8 + T-cell atlas and identified the kinase FYN as a marker of Tpex cells in ICB responders. FYN deficiency in CD8 + T cells induced LCK hyperactivation, which drove terminal exhaustion under high-affinity antigen stimulation. Mechanistically, LCK hyperactivation disrupted metabolic homeostasis by triggering excessive glycolysis and impairing mitochondrial function in Tpex cells. Conversely, LCK inhibition elevated compensatory FYN activity, restored mitochondrial fitness, and preserved Tpex cell stemness. In preclinical HCC models, transient LCK inhibition during T-cell expansion enhanced adoptive cell therapy efficacy by increasing Tpex cell persistence and stemness. Additionally, preemptive low-dose LCK inhibition before anti-PD-1 therapy expanded the Tpex cell pool, reduced terminal exhaustion, and improved therapeutic outcomes. CONCLUSIONS: This study establishes the FYN/LCK balance as a critical regulator of the terminal exhaustion of Tpex cells through metabolic reprogramming. These findings suggest that modulating the FYN/LCK kinase balance is a promising strategy to overcome immunotherapy resistance in HCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。